Back to Back Issues Page
Robust Vision Gains
December 02, 2015

Robust Vision Gains

"Data from the IMPACT Phase II study demonstrated improvements in best-corrected visual acuity (BCVA) and ≥3 line gains using the combination of OHR-102 (squalamine eye drops) and Lucentis as compared to the Lucentis monotherapy group at all timepoints from 4 to 38 weeks.

We believe this robust and rapid response to OHR-102 is a result of its potent inhibition of multiple angiogenic targets," said Dr. Jason Slakter, Chief Medical Officer of Ohr and retina specialist.

The treatments that have been developed and that are being researched for wet macular degeneration focus on drying up the "wet" area around the macula and prevent further blood vessels from growing and leaking. Another word for the formation of these strange blood vessels under the macula is called angiogenesis - which simply means "blood vessels" and "creation."

Combination Therapy

Drugs that prevent this from happening are called anti-angiogenesis drugs. One protein that is responsible for this activity is VEGF - vascular endothelial growth factor. Hence drugs like Lucentis, Avastin and Eylea are called anti-VEGF drugs.

Positive reports were given at the November 2015 annual meeting of the American Academy of Ophthalmology on the benefits of combining Squalamine drops with Lucentis eye injections.

Squalamine not only works as an anti-VEGF medication but also inhibits other vessel growth factors like platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF).

Get the latest update on some promising results from this study that were reported at the November 2015 American Academy of Ophthalmology:

Combination Therapy Using Eye Drops and Eye Injections

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page